Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes

Abstract Post-transplant lymphoproliferative disorder (PTLD) is a well-known complication of hematopoietic stem cell transplant and solid organ transplant. While reduction in immunosuppression (RIS) is the first-line treatment for PTLD, outcomes of allograft function as a result of RIS remain understudied. In this retrospective study, we examine rates of allograft rejection and graft failure after RIS in 141 patients diagnosed with PTLD at the University of Florida. Compared to prior literature demonstrating around 32–40% rate of allograft rejection as result of RIS, our institutional analysis revealed a much lower treatment-related allograft rejection rate of 18.4%. Out of the patients who experienced acute allograft rejection, 23.1% ultimately progressed to allograft failure. Interestingly, acute allograft rejection episodes during PTLD treatment were not statistically found to impact overall survival. RIS remains an overall beneficial treatment modality of PTLD due to its low allograft rejection rate relative to treatment rate.

[1]  Zhenchang Wang,et al.  Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts , 2018, Medicine.

[2]  T. Habermann,et al.  Post‐Transplantation Lymphoproliferative Disorders in Adults , 2018, The New England journal of medicine.

[3]  N. Dang,et al.  Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients , 2017, Experimental Hematology & Oncology.

[4]  Riccardo Dolcetti,et al.  Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. , 2015, Cancer letters.

[5]  N. Kamar,et al.  CNI withdrawal for post‐transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  A. Evens,et al.  Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies , 2013, Current Hematologic Malignancy Reports.

[7]  M. Michaels,et al.  Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  B. Woda,et al.  Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations , 2012, Current Treatment Options in Oncology.

[9]  D. Heitjan,et al.  Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★ , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  R. Marcus,et al.  Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.

[11]  Scott E. Smith,et al.  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Alan M. Miller,et al.  Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder , 2008, Transplantation.

[13]  B. Somer,et al.  REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 , 2001, Transplantation.